| Literature DB >> 30952921 |
Micaela A Macchione1,2, Carlos Guerrero-Beltrán3,4,5,6, Anabella P Rosso1,2, Esteban M Euti1,2, Marisa Martinelli1,2, Miriam C Strumia7,8, Maria Ángeles Muñoz-Fernández9,10,11,12.
Abstract
Stimuli-responsive nanogels offer promising perspectives for the development of next generation formulations for biomedical applications. In this work, poly(N-vinylcaprolactam) nanogels were synthesized varying the concentration of monomer and crosslinking agent. Thus, the inhibitory effect of poly(N-vinylcaprolactam) nanogels against HIV-1 infection is presented for the first time. In particular, we have demonstrated that one of the synthesized poly(N-vinylcaprolactam) nanogels with initial concentration of 80 mg of vinylcaprolactam and 4% of crosslinking agent shows antiviral behavior against HIV-1 infection since this nanogel inhibits the viral replication in TZM.bl target cells.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30952921 PMCID: PMC6450967 DOI: 10.1038/s41598-019-42150-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Series of NGs from PVCL prepared by thermo-precipitation in aqueous phase.
Figure 2FT-IR spectra of PVCL NGs.
Figure 31H-NMR spectra of VCL monomer and PVCL NG.
Figure 4Average hydrodynamic diameters of the synthesized NGs as a function of the temperature of the medium.
Average hydrodynamic diameters (Dh), phase transition temperatures (Tp) and cloud point temperatures (Tcp) of the synthesized NGs.
| Sample | Dh* (nm) | Tp (°C) | Tcp (°C) |
|---|---|---|---|
| PVCL800 | 68 | 31.8 | 33.3 |
| PVCL801 | 73 | 32.5 | 32.3 |
| PVCL802 | 148 | 32.1 | 32.1 |
| PVCL804 | 205 | 24.4 | 25.2 |
| PVCL600 | 28 | 34.5 | 34.7 |
| PVCL604 | 142 | 33.4 | 33.5 |
| PVCL6010 | 164 | 31.9 | 32.6 |
*Dh measured in the swollen state below the transition phase temperature of the NGs.
Figure 5TEM images and size distribution of: PVCL804 (a,b) and PVCL600 (c,d).
Figure 6TGA curves of synthetized NGs with different concentration of crosslinker.
Figure 7Biocompatibility assays of PVCL804 NG. MTT assay was performed on TZM.bl cells after 48 h of PVCL804 exposure. TZM.bl cells were treated in range concentrations between 0.01 and 100 μg/mL. Medium alone (NTC) and DMSO were used as untreated and cell death controls, respectively. Data is presented as the mean ± SD of three individual experiments performed in triplicate. Abbreviations: NTC = non-treated control; DMSO = dimethyl sulfoxide.
Figure 8Anti-HIV-1 activity of PVCL804 NG. TZM.bl cells were treated with PVCL804 at several non-toxic concentrations (10 µg/mL, 5 µg/mL and 1 µg/mL) or controls (G2-S16, 10 µM) for 1 h before infection with R5-HIV-1NLAD8 isolate (30 ng of p24/106 cells) for 2 h. The percentage of infection was determined at 48 h post-infection by measuring luciferase activity (vs. CI). Data is presented as the mean ± SD of three independent experiments performed in triplicate. Abbreviations: CI = control of infection.